Restricted Mean Survival Time as Outcome Measure in Advanced Urothelial Bladder Cancer: Analysis of 4 Clinical Studies
- 5 November 2020
- journal article
- research article
- Published by Taylor & Francis in Immunotherapy
- Vol. 13 (2) , 95-101
Abstract
Background: The purpose of this study was to assess the effectiveness of immune checkpoint inhibitors (ICIs) in advanced urothelial carcinoma. Materials & methods: We selected seven cohorts of patients published in four clinical trials. The restricted mean survival time (RMST) was used to analyze survival curves, perform the comparisons and rank the treatments based on their effectiveness. The performance of RMST was compared with that of a network meta-analysis. Results: Three ICIs, vinflunine and best standard care, given as second line, were examined. ICIs significantly improved overall survival compared with best standard care. However, the survival gain was quite limited (up to 2.27 months). Post hoc pairwise comparisons were calculated. Conclusion: Our results summarized the efficacy of these treatments and confirmed the good methodological performance of RMST.Keywords
This publication has 27 references indexed in Scilit:
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trialThe Lancet Oncology, 2017
- Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials?Journal of Clinical Oncology, 2016
- The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysisOncotarget, 2016
- Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled TrialsJournal of Clinical Oncology, 2016
- Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysisAnnals of Oncology, 2016
- Cisplatin-Ineligible and Chemotherapy-Ineligible Patients Should Be the Focus of New Drug Development in Patients With Advanced Bladder CancerClinical Genitourinary Cancer, 2014
- Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987Journal of Clinical Oncology, 2012
- Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based ChemotherapyJournal of Clinical Oncology, 2011
- Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial TractJournal of Clinical Oncology, 2009
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005